PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia

Enriched recordOpen access

Abstract

No public abstract is available from the verified source records.

Authors

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

europepmc

Confidence 96%

unpaywall

Confidence 95%

datacite

Confidence 0%

Referenced works

No local reference links have been materialized yet.

No local citing links have been materialized yet.

Unresolved referenced work

Kept as external metadata until matched

10.1056/nejmoa2511065

10.1056/nejmoa2511065 · 2025

10.1200/jco-25-01651

10.1200/jco-25-01651 · 2025

10.1056/nejmoa2004444

10.1056/nejmoa2004444 · 2020

10.1056/nejmoa1805131

10.1056/nejmoa1805131 · 2018

10.1056/nejmoa2502449

10.1056/nejmoa2502449 · 2025

10.1016/s0140-6736(25)01897-5

10.1016/s0140-6736(25)01897-5 · 2025

10.1016/s2352-3026(25)00264-9

10.1016/s2352-3026(25)00264-9 · 2025

Unresolved referenced work

Kept as external metadata until matched

No additional external references are available.